Results 91 to 100 of about 66,971 (207)

Mutations in gyrB play an important role in ciprofloxacin-resistant Pseudomonas aeruginosa

Infection and Drug Resistance, 2019
Xinyuan Feng,1,* Zhiqi Zhang,2,* Xiaoxia Li,3 Yan Song,3 Jianbang Kang,3 Donghong Yin,3 Yating Gao,3 Nan Shi,1 Jinju Duan3 1Department of Pharmacy, School of Pharmacy, Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China ...
Feng X, Zhang Z, Li X, Song Y, Kang J, Yin D, Gao Y, Shi N, Duan J   +8 more
doaj  

Physicochemical properties of fluoroquinolones.

, 2013
Molecular weights, Partition Coefficients (ClogP), Polar Surface Areas (PSA) and relative spermidine-induced reductions in intracellular accumulation of four fluoroquinolones (as illustrated in Figure 3A).
Jansy Passiflora Sarathy (417716), Edmund Lee (76196), Véronique Dartois (193696)   +2 more
core   +1 more source

Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada

, 2011
Ciprofloxacin, the first fluoroquinolone to be used to treat lower respiratory tract infections (LRTI), demonstrates poor potency against Streptococcus pneumoniae , and its use has been associated with the emergence of resistance.
Karen Green, null null, Allison McGeer, Dylan R. Pillai, Gregory J. Tyrrell, Donald E. Low, Samir N. Patel, Roberto Melano   +7 more
core   +1 more source

Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally.

, 2010
BACKGROUND: Malaria in humans is caused by apicomplexan parasites belonging to 5 species of the genus Plasmodium. Infections with Plasmodium ovale are widely distributed but rarely investigated, and the resulting burden of disease is not known ...
Dolecek, C., Dolecek, Christiane, Pinto, J., Barnwell, JW, Chiodini, Peter L, Tanomsing, N, Nolder, D, Sutherland, Colin J, do Rosário, VE, Escalante, Ananias A, do Rosário, Virgilio E., Michon, Pascal, Oguike, M, Lee, R, Barnwell, John W., Escalante, Ananias A., Pain, A., Oguike, M., Burke, M., Day, Nicholas PJ, Burke, M, Blaze, Marie, Blaze, M., Escalante, AA, Escalante, A.A., Nolder, Debbie, Lockhart, PJ, Lee, R., Williams, John, Snounou, Georges, Imwong, Mallika, Pinto, J, Oguike, Mary, Hien, Tran, Lockhart, Peter J., Lockhart, Peter J, Barnwell, John W, White, Nicholas, Day, N.P.J., Burke, Martina, Arez, AP, Williams, J., Hien, TT, Hien, Tran Tinh, Arez, A.P., Sutherland, CJ, White, Nicholas J., Michon, P., Imwong, M., Polley, S.D., Nosten, F., Barnwell, J.W., Nolder, D., Arez, Ana Paula, Hien, T.T., Day, Nicholas P. J., Polley, SD, do Rosário, Virgilio E, Jennison, C, Pukrittayakamee, S., White, Nicholas J, Pukrittayakamee, S, Jennison, Charlie, Otto, TD, Day, NP, Tanomsing, N., Polley, Spencer D, Nosten, F, Michon, P, Pain, Arnab, Pinto, João, Pukrittayakamee, Sasithon, Chiodini, P.L., Pain, A, Do Rosário, V.E., Snounou, G., Blaze, M, Sutherland, Colin J., Imwong, M, Day, Nicholas, Chiodini, Peter L., Nosten, Francois, Lockhart, P.J., Tanomsing, Naowarat, Dolecek, C, Williams, J, White, NJ, Snounou, G, Sutherland, C.J., Polley, Spencer D., White, N.J., Jennison, C., Chiodini, PL, Otto, Thomas Dan, Lee, Rogan, Otto, T.D.   +95 more
core   +1 more source

Fluoroquinolones as imaging agents for bacterial infection

, 2017
Three ways to radioactively label fluoroquinolones are available, thereby creating multiple options for developing a diagnostic for deep-seated bacterial infection.
Syed Ali Raza Naqvi, Karl Drlica
core   +1 more source

Cardiovascular and metabolic safety profiles of the fluoroquinolones

, 2012
Introduction: Certain fluoroquinolones share similar indications of use. A comparison among Cardiovascular and metabolic (i.e., dysglycemia) safety profiles of the fluoroquinolones might be particularly useful for the prescribers' decision-making process
VANNACCI A., LONGO L., LAPI F., ROSSOLINI G. M., MUGELLI A., BARTOLONI A., PUGI A.   +6 more
core   +1 more source

Allergies et effets indésirabtes dus aux fluoroquinolones [Allergies and adverse events associated with fluoroquinolones]

, 2015
The prescription ot fluoroquinolones has been constantly increasing over the past decade. consequently, an increasing number of hyper-sensitivity reactions and adverse events have been reported.
Harr, T., Emonet, S., Muller, Y., Andrey, D., Spoerl, D.   +4 more
core  

Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).

, 2020
Currently the World Health Organization only recommend fluoroquinolones for people with presumed drug-sensitive tuberculosis (TB) who cannot take standard first-line drugs.
Ziganshina L., Titarenko A., Davies G.
core  

Fluoroquinolones (FQs) effects on enterocytes and lymphocytes.

, 2003
The aim was to study fluoroquinolones intestinal concentrations and their potential interference with cells. Our preliminary results indicate that fluoroquinolones present different pharmacokinetic properties in relation to intestianal concentrations and
BERTAZZONI MINELLI, Elisa, BENINI, Anna, DORIA, Denise, FRANCESCHETTI, Paola, FRACASSO, Maria Enrica   +4 more
core  

Relative optical density of ICSAs against fluoroquinolones.

Relative optical density of ICSAs against fluoroquinolones.
Sharon Kwee (6718295), Xingdong Yang (550124), Qingmei Li (301661), Qianqian Zhang (587342), Jifei Yang (106735), Xiaofei Hu (639196)   +5 more
core   +1 more source